5,626 Shares in Revolution Medicines, Inc. (NASDAQ:RVMD) Purchased by Halpern Financial Inc.

Halpern Financial Inc. acquired a new position in Revolution Medicines, Inc. (NASDAQ:RVMD) during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 5,626 shares of the company’s stock, valued at approximately $259,000.

Several other large investors also recently bought and sold shares of RVMD. Nisa Investment Advisors LLC boosted its stake in shares of Revolution Medicines by 10.5% in the second quarter. Nisa Investment Advisors LLC now owns 3,378 shares of the company’s stock worth $131,000 after acquiring an additional 320 shares during the last quarter. Amalgamated Bank lifted its holdings in Revolution Medicines by 7.4% in the 2nd quarter. Amalgamated Bank now owns 5,272 shares of the company’s stock valued at $205,000 after purchasing an additional 365 shares in the last quarter. Headlands Technologies LLC boosted its stake in Revolution Medicines by 140.9% during the 1st quarter. Headlands Technologies LLC now owns 1,513 shares of the company’s stock worth $49,000 after purchasing an additional 885 shares during the last quarter. Clear Harbor Asset Management LLC grew its holdings in shares of Revolution Medicines by 10.2% during the second quarter. Clear Harbor Asset Management LLC now owns 11,224 shares of the company’s stock worth $436,000 after buying an additional 1,036 shares in the last quarter. Finally, Seven Eight Capital LP raised its position in shares of Revolution Medicines by 1.6% in the second quarter. Seven Eight Capital LP now owns 69,602 shares of the company’s stock valued at $2,701,000 after buying an additional 1,108 shares during the last quarter. 94.34% of the stock is currently owned by hedge funds and other institutional investors.

Revolution Medicines Trading Up 2.6 %

NASDAQ RVMD traded up $1.19 during trading hours on Friday, reaching $47.32. The company had a trading volume of 1,081,758 shares, compared to its average volume of 1,323,641. The stock has a market capitalization of $7.81 billion, a P/E ratio of -12.62 and a beta of 1.43. The stock has a 50-day moving average of $43.69 and a 200 day moving average of $40.02. Revolution Medicines, Inc. has a 1-year low of $15.44 and a 1-year high of $48.61.

Revolution Medicines (NASDAQ:RVMD) last issued its quarterly earnings data on Wednesday, August 7th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.77) by ($0.04). The firm had revenue of $1.00 million for the quarter, compared to analysts’ expectations of $0.81 million. During the same quarter in the prior year, the company posted ($0.92) EPS. The business’s revenue was down 73.8% on a year-over-year basis. As a group, sell-side analysts predict that Revolution Medicines, Inc. will post -3.35 EPS for the current year.

Insiders Place Their Bets

In other Revolution Medicines news, insider Mark A. Goldsmith sold 10,000 shares of Revolution Medicines stock in a transaction dated Tuesday, October 1st. The stock was sold at an average price of $44.93, for a total value of $449,300.00. Following the completion of the transaction, the insider now directly owns 300,170 shares of the company’s stock, valued at $13,486,638.10. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In other Revolution Medicines news, insider Mark A. Goldsmith sold 10,000 shares of the stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $44.93, for a total transaction of $449,300.00. Following the sale, the insider now directly owns 300,170 shares in the company, valued at $13,486,638.10. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Stephen Michael Kelsey sold 16,667 shares of the business’s stock in a transaction on Monday, July 15th. The stock was sold at an average price of $46.47, for a total transaction of $774,515.49. Following the completion of the transaction, the insider now owns 269,073 shares of the company’s stock, valued at approximately $12,503,822.31. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 66,221 shares of company stock worth $3,001,637 over the last ninety days. Corporate insiders own 8.00% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on RVMD shares. JPMorgan Chase & Co. lowered their price target on shares of Revolution Medicines from $55.00 to $54.00 and set an “overweight” rating on the stock in a research report on Thursday, August 8th. Needham & Company LLC cut their price target on Revolution Medicines from $62.00 to $61.00 and set a “buy” rating for the company in a report on Thursday, August 8th. Jefferies Financial Group began coverage on Revolution Medicines in a research note on Monday, July 8th. They set a “buy” rating and a $63.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $56.00 target price on shares of Revolution Medicines in a research note on Monday, August 12th. Finally, Oppenheimer boosted their price target on shares of Revolution Medicines from $45.00 to $55.00 and gave the company an “outperform” rating in a research report on Tuesday, July 16th. Ten investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $54.00.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.